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Question {#ccr3486-sec-0001}
========

What is an important consideration for a rapidly enlarging adrenal mass that cannot be distinguished from adrenocortical carcinoma by imaging?

Answer {#ccr3486-sec-0002}
======

Adrenal oncocytoma of uncertain malignant potential is a rare cause of rapidly enlarging adrenal mass and should be an important consideration.

Discussion {#ccr3486-sec-0003}
==========

A 68‐year‐old female presented to the hospital with hypertensive emergency with a blood pressure of 210/100 mmHg. CT revealed a solid left‐sided adrenal mass: 8.4 × 5.8 × 5.7 cm, Hounsfield Units (HU) of 75 and diffuse heterogeneous enhancement with scattered central and peripheral calcifications with no necrosis (Fig. [1](#ccr3486-fig-0001){ref-type="fig"}A). This mass had increased since 2005 when measured as 2.7 × 1.9 × 2.0 cm with a HU of 22 and similar imaging characteristics (Fig. [1](#ccr3486-fig-0001){ref-type="fig"}B). Plasma metanephrine, aldosterone, renin activity, dehydroepiandrosterone sulfate, androstenedione, and 24 h urine cortisol levels were normal. She underwent adrenalectomy for concern of malignancy due to rapid enlargement. Pathology revealed adrenal oncocytoma (AOC) of uncertain malignant potential (Fig. [1](#ccr3486-fig-0001){ref-type="fig"}C). AOC is composed of cells with atypical nuclei and oncocytes that are rich in granular eosinophil cytoplasm and mitochondria [1](#ccr3486-bib-0001){ref-type="ref"}. AOC is a rare tumor with less than 150 cases reported, of which only 14 are classified as AOC of uncertain malignant potential [2](#ccr3486-bib-0002){ref-type="ref"}.

![(A) Contrast‐enhanced abdominal CT scan, arrow: adrenal nodule (2015). (B) Contrast‐enhanced abdominal CT scan, arrow: adrenal nodule (2005). (C) Hematoxylin and eosin stain; original magnification \*200 of pathologic specimen, arrow: bright oncocytic pink cytoplasm.](CCR3-4-303-g001){#ccr3486-fig-0001}
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